Tiziana Life Sciences Plc
(NASDAQ : TLSA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 1.95%69.150.0%$1917.83m
NVAXNovavax, Inc. 9.93%146.5196.5%$1301.01m
SRNESorrento Therapeutics, Inc. -4.38%12.441.5%$767.50m
GILDGilead Sciences, Inc. 0.47%68.501.0%$580.36m
AMGNAmgen, Inc. 0.36%239.711.3%$465.88m
REGNRegeneron Pharmaceuticals, Inc. 0.28%612.572.7%$378.37m
VRTXVertex Pharmaceuticals, Inc. 0.05%267.291.9%$351.81m
BIIBBiogen, Inc. 0.32%289.451.4%$344.47m
ILMNIllumina, Inc. -1.69%347.563.5%$340.75m
BNTXBioNTech SE -3.32%68.640.0%$334.95m
ATNMActinium Pharmaceuticals, Inc. -1.21%9.7913.3%$231.53m
EBSEmergent BioSolutions, Inc. -1.09%133.476.4%$198.26m
VXRTVaxart, Inc. 0.55%9.140.0%$194.27m
MCRBSeres Therapeutics, Inc. -4.62%27.263.6%$181.12m
ALXNAlexion Pharmaceuticals, Inc. 1.06%102.971.9%$162.43m

Company Profile

Tiziana Life Sciences Plc is a biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. Its lead product candidate in immunology is Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody. The company was founded by Gabriele Marco Antonio Cerrone on November 4, 2013 and is headquartered in London, the United Kingdom.